Pralatrexate : evaluation of clinical efficacy and toxicity in T-cell lymphoma.

Article Details

Citation

Copy to clipboard

Shimanovsky A, Dasanu CA

Pralatrexate : evaluation of clinical efficacy and toxicity in T-cell lymphoma.

Expert Opin Pharmacother. 2013 Mar;14(4):515-23. doi: 10.1517/14656566.2013.770474. Epub 2013 Feb 14.

PubMed ID

23409799 [ View in PubMed

]

Abstract

INTRODUCTION: Pralatrexate is a novel antifolate agent that belongs to the class of 10-deazaaminopterins. Its clinical efficacy as a single agent in relapsed or refractory peripheral T-cell lymphoma (PTCL) has been established in randomized trials. Treatment with this agent is generally safe. AREAS COVERED: This paper discusses the pharmacokinetics and efficacy of pralatrexate in T-cell lymphoma in clinical trials. In addition, the authors highlight pralatrexate-associated adverse effects and safety concerns. EXPERT OPINION: Although established as a second-line therapy, pralatrexate offers a clinical benefit to less than one-third of patients with PTCL. In addition, toxicity of this agent can be significant, especially mucositis, immunosuppression and thrombocytopenia. Currently, the potential synergy between pralatrexate and other agents in T-cell lymphoma is being explored in a number of studies. These results will hopefully prove the validity of this approach, leading to improved quantity of life in these patients, with an acceptable comfort index.

DrugBank Data that Cites this Article

Drugs

Pralatrexate

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Pralatrexate	Dihydrofolate reductase	Protein	Humans	Yes	Substrate Inhibitor	Details
Pralatrexate	Thymidylate synthase	Protein	Humans	Unknown	Substrate Inhibitor	Details